Novartis's up-to-$3.2 billion licensing deal for Alteogen's ALT-B4 hyaluronidase enzyme is the fourth subcutaneous-conversion ...
The FDA approves zilganersen, the first disease-modifying Alexander disease therapy, offering rare disease developers a trial ...
David S. Thompson, CSAP, is Chief Alliance Officer at Eli Lilly and Company.
Extending CAR T beyond cancer alters risk–benefit calculus, because chronic autoimmune populations have alternative therapies ...
Tara Dougal, event director for pharma at Informa Markets and head of CPHI Milan, previews the 2026 show in an interview with ...
Novartis obtained portfolio-level options for exclusive rights to Hybrozyme-enabled SC formulations, with economics up to ...
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor. PhD, AbbVie, and Swita Singh, PhD, Bristol ...
On August 31, 2026, Eli Lilly announced it has entered a definitive agreement to acquire Merida Biosciences, a biotechnology ...
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol ...
As increasingly complex, poorly water-soluble molecules enter development, AustinPx helps developers look beyond near-term ...
The FDA cleared four notable therapies within the same week in late August, spanning infectious disease, cardiometabolic care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results